This Is MS Multiple Sclerosis Knowledge & Support Community

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.

Gueguen A, Roux P, Deschamps R, Moulignier A, Bensa C, Savatovsky J, Heran F, Gout O.

Abstract

OBJECTIVE: To characterise recurrence of multiple sclerosis (MS) inflammatory activity during the year following natalizumab (NTZ) cessation..... Read More - http://www.ms-uk.org/tysabri

I thought the rebound was pretty much understood.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259335/

Natalizumab is an approved medication for highly active multiple sclerosis (MS). Progressive multifocal leukoencephalopathy (PML) may occur as a severe side effect of this drug. Here, we describe pathological and radiological characteristics of immune reconstitution inflammatory syndrome (IRIS), which occurs in natalizumab-associated PML after the cessation of therapy, and we differentiate it from ongoing PML.

Kind of places the potential Tysabri user in a difficult position....use the drug for more than 2 years and see the risk of PML climb higher and higher. Stop using the drug to reduce the PML risk and experience a bad rebound effect!! All this and paying over $ 60,000 a year!